About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
Industry, Sector and Symbol
Trailing P/E Ratio-100.65
Forward P/E Ratio-68.24
Sales & Book Value
Annual Sales$154.58 million
Price / Sales33.85
Price / CashN/A
Book Value$12.21 per share
Price / Book6.59
Return on Equity-30.59%
Return on Assets-22.85%
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) released its quarterly earnings data on Thursday, March, 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.05. The biotechnology company earned $57.30 million during the quarter, compared to analysts' expectations of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The business's revenue for the quarter was up 961.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.71) earnings per share. View Sarepta Therapeutics' Earnings History.
When will Sarepta Therapeutics make its next earnings announcement?
Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2018?
19 brokerages have issued 12 month price objectives for Sarepta Therapeutics' shares. Their forecasts range from $27.00 to $101.00. On average, they anticipate Sarepta Therapeutics' share price to reach $79.67 in the next twelve months. View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. According to Zacks Investment Research, "Sarepta's Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year. Loss estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (2/7/2018)
- 2. Cowen Inc analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include bluebird bio (BLUE), Alkermes (ALKS), Jazz Pharmaceuticals (JAZZ), Seattle Genetics (SGEN), Beigene (BGNE), SAGE Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Stada Arzneimittel (STDAF), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), Valeant Pharmaceuticals Intl (VRX), BIO-TECHNE (TECH), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Galapagos (GLPG), United Therapeutics (UTHR) and Swedish Orphan Bio (SWTUY).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Douglas S. Ingram, President, Chief Executive Officer (Age 54)
- Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer (Age 52)
- David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary (Age 45)
- Alexander Cumbo, Senior Vice President, Global Commercial Development (Age 46)
- Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality (Age 57)
- Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer (Age 54)
- Michael W. Bonney, Director (Age 59)
- Richard J. Barry, Independent Director (Age 58)
- M. Kathleen Behrens Ph.D., Independent Director (Age 64)
- Claude Nicaise M.D., Independent Director (Age 64)
Has Sarepta Therapeutics been receiving favorable news coverage?
News articles about SRPT stock have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 0.22 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.78 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.73%), Fred Alger Management Inc. (2.45%), HealthCor Management L.P. (2.03%), Jennison Associates LLC (1.78%), Eagle Asset Management Inc. (1.53%) and Emerald Advisers Inc. PA (1.37%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Jayant Aphale, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which major investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Quantitative Investment Management LLC, Tekla Capital Management LLC, Sphera Funds Management LTD., HealthCor Management L.P., J. Goldman & Co LP, Alliancebernstein L.P. and QVT Financial LP. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.
Which major investors are buying Sarepta Therapeutics stock?
SRPT stock was purchased by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Gilder Gagnon Howe & Co. LLC, Element Capital Management LLC, Sectoral Asset Management Inc, Fuller & Thaler Asset Management Inc., Fred Alger Management Inc., Stansberry Asset Management LLC and Alps Advisors Inc.. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $80.52.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $5.26 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (SRPT)MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sarepta Therapeutics (NASDAQ:SRPT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.89||2.84||2.80||2.75|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$79.67||$67.11||$66.11||$63.70|
|Price Target Upside: ||1.05% downside||21.70% upside||18.74% upside||37.82% upside|
Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History
Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History
(Data available from 3/20/2016 forward)
Sarepta Therapeutics (NASDAQ:SRPT) Earnings History and Estimates Chart
Sarepta Therapeutics (NASDAQ SRPT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2018||Q4 2017||($0.32)||($0.37)||$57.33 million||$57.30 million||View||Listen|
|10/25/2017||Q3 2017||($0.86)||($0.20)||$41.29 million||$45.95 million||View||N/A|
|7/19/2017||Q2 2017||($0.92)||($0.46)||$22.52 million||$35.01 million||View||N/A|
|4/27/2017||Q1 2017||($0.85)||($0.73)||$13.80 million||$16.34 million||View||N/A|
|2/28/2017||Q416||($1.33)||($0.71)||$4.86 million||$5.42 million||View||Listen|
|8/6/2015||Q215||($1.21)||($1.01)||$0.31 million||$0.01 million||View||Listen|
|2/26/2015||Q414||($0.82)||($0.94)||$1.56 million||$0.30 million||View||Listen|
|11/6/2014||Q314||($0.96)||($0.70)||$3.07 million||$1.10 million||View||Listen|
|8/7/2014||Q214||($0.76)||($0.85)||$4.30 million||$2.58 million||View||Listen|
|5/8/2014||Q114||($0.80)||($0.75)||$3.45 million||$6.09 million||View||Listen|
|2/27/2014||Q413||($0.69)||($0.77)||$4.53 million||$2.60 million||View||Listen|
|11/12/2013||Q313||($0.65)||($0.63)||$4.57 million||$4.20 million||View||Listen|
|8/8/2013||Q2 2013||($0.67)||($0.46)||$5.08 million||$3.00 million||View||Listen|
|5/9/2013||Q1 2013||($0.62)||($0.41)||$5.85 million||$4.50 million||View||Listen|
|3/7/2013||Q4 2012||($0.26)||($2.36)||$6.71 million||$7.30 million||View||Listen|
|11/7/2012||($0.27)||($2.17)||$10.06 million||$7.57 million||View||N/A|
Sarepta Therapeutics (NASDAQ:SRPT) Earnings Estimates
2018 EPS Consensus Estimate: ($1.24)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by MarketBeat.com
Sarepta Therapeutics (NASDAQ SRPT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 84.93%
Sarepta Therapeutics (NASDAQ SRPT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/30/2017||Hans Lennart Rudolf Wigzell||Director||Sell||6,667||$55.89||$372,618.63||13,333|| |
|11/8/2017||Douglas S Ingram||CEO||Buy||38,138||$52.44||$1,999,956.72||420,196|| |
|11/6/2017||Shamim Ruff||SVP||Sell||10,000||$55.00||$550,000.00||37,045|| |
|10/3/2017||Shamim Ruff||SVP||Sell||11,500||$50.00||$575,000.00|| |
|7/27/2017||Douglas S Ingram||CEO||Buy||47,058||$42.50||$1,999,965.00||382,058|| |
|7/21/2017||Shamim Ruff||SVP||Sell||12,138||$42.97||$521,569.86||27,312|| |
|7/20/2017||Alexander Cumbo||SVP||Sell||5,918||$41.00||$242,638.00||22,793|| |
|7/20/2017||Edward M Md Kaye||Director||Sell||10,000||$41.00||$410,000.00||62,471|| |
|7/20/2017||Sandesh Mahatme||CFO||Sell||50,000||$41.00||$2,050,000.00||41,736|| |
|10/17/2016||Sandesh Mahatme||Insider||Sell||30,000||$50.08||$1,502,400.00||61,532|| |
|9/22/2016||David T Howton||SVP||Sell||7,000||$60.00||$420,000.00||28,453|| |
|9/22/2016||Edward M Md Kaye||CEO||Sell||40,179||$60.00||$2,410,740.00||117,162|| |
|9/19/2016||David T Howton||SVP||Sell||9,304||$50.00||$465,200.00||11,168|| |
|9/19/2016||Edward M Md Kaye||CEO||Sell||24,352||$50.00||$1,217,600.00||89,983|| |
|9/19/2016||Jayant Aphale||VP||Sell||35,000||$50.00||$1,750,000.00||21,490|| |
|9/14/2016||Edward M Md Kaye||CEO||Sell||24,557||$30.00||$736,710.00||76,983|| |
|3/16/2016||M Kathleen Behrens||Director||Buy||10,000||$14.54||$145,400.00||112,166|| |
|3/14/2016||M Kathleen Behrens||Director||Buy||65,000||$16.54||$1,075,100.00||112,166|| |
|11/14/2013||Anthony Chase||Director||Buy||10,000||$13.95||$139,500.00||41,744|| |
|9/16/2013||M Kathleen Behrens||Director||Buy||6,500||$37.04||$240,760.00||44,166|| |
|9/3/2013||John Hodgman||Director||Sell||5,556||$34.97||$194,293.32|| |
|8/22/2013||Anthony Chase||Director||Buy||3,500||$32.68||$114,380.00||31,744|| |
|8/20/2013||Sandesh Mahatme||CFO||Buy||5,000||$31.10||$155,500.00||5,000|| |
|6/14/2013||Anthony R Chase||Director||Buy||10,000||$38.50||$385,000.00|| |
|9/7/2012||M Kathleen Behrens||Director||Buy||17,500||$14.73||$257,775.00|| |
Sarepta Therapeutics (NASDAQ SRPT) News Headlines
Sarepta Therapeutics (NASDAQ:SRPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sarepta Therapeutics (NASDAQ:SRPT) Income Statement, Balance Sheet and Cash Flow Statement
Sarepta Therapeutics (NASDAQ SRPT) Stock Chart for Tuesday, March, 20, 2018